Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy
Follicular Lymphoma (FL)
CD20 monoclonal antibody
1. Approved Labelling
Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
2. Treatment Regimen
The recommended dose of Truxima in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Truxima should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable.
Please see section 4.4 of the SmPC
All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.